Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes
暂无分享,去创建一个
H. Kantarjian | G. Garcia-Manero | F. Ravandi | E. Jabbour | H. Carraway | N. Pemmaraju | A. Advani | M. Sekeres | A. Nazha | S. Mukherjee | A. Gerds | Y. Alvarado | M. Kurman | L. Bavisotto | H. Iwamura | K. Naqvi | M. Johansen | Ricardo De Lumpa | Motohiko Murase | G. Maier
[1] L. Pleyer,et al. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. , 2018, Blood advances.
[2] Tae Kon Kim,et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. , 2018, Blood advances.
[3] Y. Kanakura,et al. Molecular targeting of inosine-5’-monophosphate dehydrogenase by FF-10501 promotes erythropoiesis via ROS/MAPK pathway , 2018, Leukemia & lymphoma.
[4] G. Garcia-Manero,et al. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. , 2017, Leukemia research.
[5] Y. Hayashi,et al. Inhibition of Impdh As an Effective Treatment for MLL-Fusion Leukemia , 2016 .
[6] J. Barnard,et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure , 2016, Haematologica.
[7] Y. Shimada,et al. Lack of cross‐resistance to FF‐10501, an inhibitor of inosine‐5′‐monophosphate dehydrogenase, in azacitidine‐resistant cell lines selected from SKM‐1 and MOLM‐13 leukemia cell lines , 2016, Pharmacology research & perspectives.
[8] M. Konopleva,et al. Survival Outcomes in Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-than-Complete Response After First Salvage Therapy , 2014 .
[9] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[10] B. Esterni,et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Strovel,et al. A phase I trial of AVN944 in patients with advanced hematologic malignancies , 2007 .
[12] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[13] J. Sherley,et al. Immortal DNA strand cosegregation requires p53/IMPDH-dependent asymmetric self-renewal associated with adult stem cells. , 2005, Cancer research.
[14] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Grusch,et al. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. , 1999, Current medicinal chemistry.
[16] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[17] F. Collart,et al. Increased IMP dehydrogenase gene expression in solid tumor tissues and tumor cell lines , 1992 .
[18] N. Heerema,et al. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. , 1989, Cancer research.
[19] K. Yamada,et al. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies]. , 1989, Gan to kagaku ryoho. Cancer & chemotherapy.